Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | PARP10 | Q53GL7 | 7/20 | 0.54 |
| ▸ | MAOB | P27338 | 2/20 | 0.54 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.54 |
| ▸ | PARP14 | Q460N5 | 2/20 | 0.54 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.51 |
| ▸ | PTPRC | P08575 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.49 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.49 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.49 |
| ▸ | TMPRSS6 | Q8IU80 | 1/20 | 0.49 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1368181 | 0.85 | TP53 (0.63) | KDM4ESMN1; SMN2PTPRCPTPN1CAPN1 | |
| SCHEMBL23358421 | 0.84 | PARP10 (0.50) | KDM4EPARP10MAOBPARP15PARP14 | |
| SCHEMBL8587673 | 0.83 | MAOB (0.61) | PARP10MAOBPARP15PARP14SIRT2 | |
| SCHEMBL6940590 | 0.83 | MEN1 (0.60) | KDM4ESMN1; SMN2PARP10MAOBPARP15 | |
| SCHEMBL4180620 | 0.83 | PARP10 (0.56) | KDM4ESMN1; SMN2PARP10CTNNB1SIRT2 | |
| SCHEMBL10061345 | 0.82 | MAOB (0.55) | KDM4ESMN1; SMN2MAOBPTPRCPTPN1 | |
| SCHEMBL8076831 | 0.82 | PTPRC (0.51) | KDM4ESMN1; SMN2MAOBPTPRCPTPN1 | |
| SCHEMBL15676701 | 0.81 | NPC1 (0.49) | KDM4ESMN1; SMN2PARP10MAOBPARP15 | |
| SCHEMBL18773849 | 0.81 | APP (0.46) | KDM4ESMN1; SMN2PARP10MAOBPARP15 | |
| SCHEMBL27482417 | 0.81 | PTPRC (0.54) | KDM4ESMN1; SMN2MAOBPTPRCPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1997003967-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND THEIR PHARMACEUTICAL USE | RHONE-POULENC RORER LIMITED (GB) | 1997-02-06 | — | — | WO | claimed |
| EP-2780014-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | Constellation Pharmaceuticals, Inc. (US) | 2014-09-24 | — | — | EP | disclosed |
| CN-102245021-B | Ansamycin hydroquinone compositions | INFINITY DISCOVERY INC | 2014-09-17 | — | — | CN | disclosed |
| CN-103502219-A | Novel small-molecules as therapeutics | BIONOMICS LTD | 2014-01-08 | — | — | CN | disclosed |
| CN-103333330-A | Polycarbonate polyol compositions and methods | NOVOMER INC | 2013-10-02 | — | — | CN | disclosed |
| WO-2013075083-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS (US) | 2013-05-23 | — | — | WO | disclosed |
| CN-102149746-B | Polycarbonate polyol compositions and methods | NOVOMER INC | 2013-05-22 | — | — | CN | disclosed |
| EP-2205576-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2010-07-14 | — | — | EP | disclosed |
| US-7727997-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| EP-2125703-A2 | NEW N-(3-PHENYLPROPYL)BENZAMIDE DERIVATIVES | Bayer CropScience SA (FR) | 2009-12-02 | — | — | EP | disclosed |
| WO-2009047558-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | WO | disclosed |
| WO-2008101975-A2 | NEW N-(3-PHENYLPROPYL)BENZAMIDE DERIVATIVES | BAYER CROPSCIENCE SA (FR) | 2008-08-28 | — | — | WO | disclosed |
| US-20080090863-A1 | Pyridine Derivatives and Their Use as Medicaments for Treating Diseases Related to Mch Receptor | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-17 | — | — | US | disclosed |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | ELAN PHARMACEUTICALS, INC. | 2007-09-13 | — | — | US | disclosed |
| US-7176242-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
| WO-1997003967-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND THEIR PHARMACEUTICAL USE | RHONE-POULENC RORER LIMITED (GB) | 1997-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090863-A1 | Pyridine Derivatives and Their Use as Medicaments for Treating Diseases Related to Mch Receptor | MCHR1, GPR119, MCHR2 | KDM4E 628/4885SMN1; SMN2 1609/4885PARP10 2464/4885 |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | KDM4E 1190/4885SMN1; SMN2 1477/4885PARP10 2967/4885 |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | BACE1, BACE2, APP | KDM4E 4082/4885SMN1; SMN2 1298/4885PARP10 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.